AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18180889 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Wuzi Yanzong Granule (WYG)
Number of subjects: 36
Study 18180889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18180889 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (20 healthy subjects)
Number of subjects: 36
Study 15359927 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinjection transmission scan
Number of subjects: 10
Study 15359927 — intervention group
Group type: COMPARATOR
Intervention: Preinjection transmission scan
Number of subjects: 10
Study 11486790 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (OLS) 120 mg three times daily
Number of subjects: 30
Study 11486790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10676140 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with the concept of neediness
Number of subjects: 0
Study 10676140 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with the concept of safety
Number of subjects: 0
Study 10676140 — intervention group
Group type: COMPARATOR
Intervention: Neutral concept activation
Number of subjects: 0
Study 10676140 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjective rating task
Number of subjects: 0
Study 9349964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with 'Flowtron DVT' garments followed by Enoxaparin
Number of subjects: 44
Study 9349964 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin alone
Number of subjects: 44
Study 8252746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl oestradiol (20 micrograms)
Number of subjects: 6
Study 8252746 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (1.25 mg Premarin)
Number of subjects: 6
Study 8252746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (2 mg)
Number of subjects: 6
Study 3545477 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg metolazone
Number of subjects: 269
Study 3545477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg metolazone
Number of subjects: 269
Study 3545477 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg metolazone
Number of subjects: 269
Study 3545477 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg older metolazone
Number of subjects: 269
Study 3545477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 3545477 — intervention group
Group type: EXPERIMENTAL
Intervention: All metolazone groups
Number of subjects: 269
Study 28939190 — intervention group
Group type: EXPERIMENTAL
Intervention: SARME without pterygomaxillary disjunction (PD)
Number of subjects: 24
Study 28939190 — intervention group
Group type: EXPERIMENTAL
Intervention: SARME with pterygomaxillary disjunction (PD)
Number of subjects: 24
Study 28939190 — intervention group
Group type: COMPARATOR
Intervention: Control group (SARME with PD)
Number of subjects: 24
Study 27707550 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab (RBZ)
Number of subjects: 152
Study 27707550 — intervention group
Group type: COMPARATOR
Intervention: 2.0 mg ranibizumab (RBZ)
Number of subjects: 152
Study 24891437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) targeting high ferritin (400-600 µg/L)
Number of subjects: 626
Study 24891437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) targeting low ferritin (100-200 µg/L)
Number of subjects: 626
Study 24891437 — intervention group
Group type: COMPARATOR
Intervention: Oral iron therapy
Number of subjects: 626
Study 22653940 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT) workshop
Number of subjects: 265
Study 22653940 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Training (LIT) self-study
Number of subjects: 265
Study 22653940 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 265
Study 22653940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (HIT and LIT)
Number of subjects: 265
Study 22653940 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT and LIT with reimbursement
Number of subjects: 265
Study 20308250 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) infusion at 125 mg kg(1) h(1) for 15 min and then at 25 mg kg(1) h(1) for 20 min before and throughout exercise
Number of subjects: 9
Study 20308250 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 9
Study 18400273 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable transrectal needle guide
Number of subjects: 198
Study 18400273 — intervention group
Group type: COMPARATOR
Intervention: Reusable needle guide
Number of subjects: 198
Study 15807179 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 28
Study 15807179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12470771 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (10 microg intradermal injection)
Number of subjects: 45
Study 10635286 — intervention group
Group type: EXPERIMENTAL
Intervention: Test gum
Number of subjects: 12
Study 10635286 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsweetened gum base
Number of subjects: 12
Study 10635286 — intervention group
Group type: COMPARATOR
Intervention: No gum (control)
Number of subjects: 12
Study 7489776 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 49
Study 7489776 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 49
Study 7489776 — intervention group
Group type: COMPARATOR
Intervention: Control (coffee-free period)
Number of subjects: 49
Study 2024792 — intervention group
Group type: EXPERIMENTAL
Intervention: IV phenytoin
Number of subjects: 55
Study 2024792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31144568 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/day; baseline: 5 days; 12 months later: 3 days)
Number of subjects: 0
Study 31144568 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (for patients with highly active disease)
Number of subjects: 0
Study 31144568 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study 31144568 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous interferon beta‐1a (SC IFNB‐1a)
Number of subjects: 0
Study 30045423 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with beverage powder containing 7 mg isotopically labeled iron (57Fe/58Fe) as Fe4(P2O7)3 and equimolar proportions of ascorbic acid
Number of subjects: 25
Study 30045423 — intervention group
Group type: COMPARATOR
Intervention: Milk fortified with energy, calcium and iron equivalent beverage powder
Number of subjects: 25
Study 26995678 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component, clinic-based HIV prevention intervention
Number of subjects: 3522
Study 26995678 — intervention group
Group type: COMPARATOR
Intervention: Control (comparison clinics)
Number of subjects: 3522
Study 24615745 — intervention group
Group type: COMPARATOR
Intervention: AC (100 mg aspirin plus 75 mg clopidogrel)
Number of subjects: 20
Study 24615745 — intervention group
Group type: EXPERIMENTAL
Intervention: ACH (AC plus 20 mg famotidine twice-daily)
Number of subjects: 20
Study 23073360 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of MgCl2 5% solution (equivalent to 382 mg of magnesium), daily for three months
Number of subjects: 26
Study 23073360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 20963535 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (0.3, 1 and 10 μg/kg intravenous; 0.1, 0.3, 1, and 2 μg/kg subcutaneous)
Number of subjects: 32
Study 20963535 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dosing of Romiplostim
Number of subjects: 32
Study 20963535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing intervals ≥2 weeks of Romiplostim
Number of subjects: 32
Study 18242155 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg i.v.
Number of subjects: 21
Study 18242155 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 15936187 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min lockout interval
Number of subjects: 60
Study 15936187 — intervention group
Group type: COMPARATOR
Intervention: 15-min lockout interval
Number of subjects: 60
Study 14661614 — intervention group
Group type: EXPERIMENTAL
Intervention: PEA‐BP
Number of subjects: 93
Study 11013539 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual art programme (dialogues using pictures of works of art)
Number of subjects: 40
Study 11013539 — intervention group
Group type: COMPARATOR
Intervention: Control group (dialogues about daily events)
Number of subjects: 40
Study 8780818 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine plus ZDV (200 mg daily for 2 weeks followed by 200 mg twice daily for 26 weeks)
Number of subjects: 49
Study 8780818 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine plus ZDV
Number of subjects: 49
Study 1600865 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocarnitine propionyl
Number of subjects: 142
Study 1600865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 6365232 — intervention group
Group type: EXPERIMENTAL
Intervention: Niopam (iopamidol)
Number of subjects: 20
Study 6365232 — intervention group
Group type: COMPARATOR
Intervention: Conray (meglumine iothalamate)
Number of subjects: 20
Study 30255454 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp cooling (CAP)
Number of subjects: 79
Study 30255454 — intervention group
Group type: COMPARATOR
Intervention: Observation (NoCAP)
Number of subjects: 79
Study 30268263 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) in EEC group
Number of subjects: 86
Study 30268263 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) in NEC group
Number of subjects: 86
Study 30268263 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (UC)
Number of subjects: 86
Study 30268263 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 86
Study 26556733 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid infusion
Number of subjects: 79
Study 26556733 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 79
Study 24166063 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × ‐RDA
Number of subjects: 39
Study 24166063 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × ‐RDA
Number of subjects: 39
Study 24166063 — intervention group
Group type: COMPARATOR
Intervention: RDA
Number of subjects: 39
Study 22647480 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 0
Study 22647480 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 0
Study 21137649 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg IM
Number of subjects: 150
Study 21137649 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg IM
Number of subjects: 150
Study 17923601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter plus clinical assessment
Number of subjects: 433
Study 17923601 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 433
Study 15704485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin 30 ml
Number of subjects: 0
Study 15704485 — intervention group
Group type: COMPARATOR
Intervention: Cerebrolysin 10 ml
Number of subjects: 0
Study 15704485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (higher dosages)
Number of subjects: 0
Study 12215163 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-high, open-toe, 30- to 40-mm Hg surgical compression stockings worn for 1 month each of 4 different brands over 4 months.
Number of subjects: 11
Study 12215163 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-high, open-toe, 30- to 40-mm Hg surgical compression stockings worn by patients in CEAP class 4.
Number of subjects: 11
Study 12215163 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-high, open-toe, 30- to 40-mm Hg surgical compression stockings worn by patients in CEAP class 5.
Number of subjects: 11
Study 12215163 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-high, open-toe, 30- to 40-mm Hg surgical compression stockings worn by patients with primary disease.
Number of subjects: 11
Study 12215163 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-high, open-toe, 30- to 40-mm Hg surgical compression stockings (all brands).
Number of subjects: 11
Study 9468736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine cue
Number of subjects: 30
Study 9468736 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousing cue
Number of subjects: 30
Study 9468736 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral cue
Number of subjects: 30
Study 9468736 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual cue modality
Number of subjects: 30
Study 9468736 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio cue modality
Number of subjects: 30
Study 9468736 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cue modality
Number of subjects: 30
Study 8548332 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV), n = 28
Number of subjects: 47
Study 8548332 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 19
Number of subjects: 47
Study 8548332 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) treatment
Number of subjects: 47
Study 2222131 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine for 10 weeks
Number of subjects: 32
Study 2222131 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine for 10 weeks
Number of subjects: 32
Study 2222131 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine after clomipramine
Number of subjects: 32
Study 2222131 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine after fluoxetine
Number of subjects: 32
Study 857192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterectal (prednacinolone, lidocaine hydrochloride, ephedrine hydrochloride)
Number of subjects: 0
Study 857192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31868074 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Mapping of Grapheme (DMG) intervention
Number of subjects: 71
Study 31868074 — intervention group
Group type: COMPARATOR
Intervention: Control condition (taught control)
Number of subjects: 71
Study 31354146 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (VL)
Number of subjects: 426
Study 31354146 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 426
Study 29179761 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingnao Kaiqiao acupuncture via intradermal needling
Number of subjects: 0
Study 24373419 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate load post-extractive implant with subepithelial connective tissue graft (grafted group)
Number of subjects: 47
Study 24373419 — intervention group
Group type: COMPARATOR
Intervention: Immediate load post-extractive implant without raising a flap (non-grafted group)
Number of subjects: 47
Study 23880005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (PEM) 500 mg/m² on day 1 + Carboplatin (CBP) AUC5 on day 1 for 21-day cycle
Number of subjects: 70
Study 23880005 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m² on days 1 and 8 + Carboplatin (CBP) AUC5 on day 1 for 21-day cycle
Number of subjects: 70
Study 20805741 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiation treatment
Number of subjects: 206
Study 20805741 — intervention group
Group type: COMPARATOR
Intervention: Sequential radiation treatment
Number of subjects: 206
Study 19486913 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (80 mg)
Number of subjects: 30
Study 19486913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17035647 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dose, 5.5 mg per day)
Number of subjects: 421
Study 17035647 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (mean dose, 56.5 mg per day)
Number of subjects: 421
Study 17035647 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose, 1.0 mg per day)
Number of subjects: 421
Study 17035647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 12854452 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 0
Study 12854452 — intervention group
Group type: COMPARATOR
Intervention: Best proven therapy
Number of subjects: 0
Study 10588784 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA flow velocity measured by TEE in patients with AF
Number of subjects: 721
Study 10588784 — intervention group
Group type: EXPERIMENTAL
Intervention: Anu(p) < 20 cm/s
Number of subjects: 721
Study 10588784 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk factors
Number of subjects: 721
Study 8723575 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (600 IU/kg twice weekly for 3 weeks)
Number of subjects: 204
Study 8723575 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 204
Study 1914563 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters changed over a guidewire at three days and removed at seven days
Number of subjects: 31
Study 1914563 — intervention group
Group type: COMPARATOR
Intervention: Catheters left in situ for seven days
Number of subjects: 31
Study 1914563 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters changed over a guidewire at three days
Number of subjects: 31
Study 6341847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular penicillin G given within 60 minutes of birth
Number of subjects: 1187
Study 6341847 — intervention group
Group type: COMPARATOR
Intervention: Control group (no penicillin treatment)
Number of subjects: 1187
Study 6341847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular penicillin G
Number of subjects: 1187
Study 29667488 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week intervention designed to increase relationship maintenance
Number of subjects: 60
Study 28640389 — intervention group
Group type: EXPERIMENTAL
Intervention: PF plus 10 μg/m2 daily rhLTα‐Da
Number of subjects: 150
Study 28640389 — intervention group
Group type: EXPERIMENTAL
Intervention: PF plus 20 μg/m2 daily rhLTα‐Da
Number of subjects: 150
Study 28640389 — intervention group
Group type: COMPARATOR
Intervention: PF alone
Number of subjects: 150
Study 26974989 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lowering of systolic blood pressure (goal < 120 mm Hg)
Number of subjects: 0
Study 26974989 — intervention group
Group type: COMPARATOR
Intervention: Currently recommended goal (< 140 mm Hg)
Number of subjects: 0
Study 24411656 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (40-min individualized education session using motivational techniques, reinforced by telephone 1 month later)
Number of subjects: 1944
Study 24411656 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 1944
Study 24411656 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual in-hospital care)
Number of subjects: 1944
Study 24411656 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1944
Study 21790794 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical CPS (1% cantharidin, 5% podophyllotoxin, 30% salicylic acid)
Number of subjects: 26
Study 21790794 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 26
Study 19258913 — intervention group
Group type: EXPERIMENTAL
Intervention: asmofilcon A contact lenses
Number of subjects: 60
Study 19258913 — intervention group
Group type: COMPARATOR
Intervention: senofilcon A contact lenses
Number of subjects: 60
Study 17580003 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (n = 24)
Number of subjects: 46
Study 17580003 — intervention group
Group type: COMPARATOR
Intervention: ECT (n = 22)
Number of subjects: 46
Study 15065029 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg/kg/dose 4 times daily)
Number of subjects: 62
Study 15065029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 11877070 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen combined with cyclosporin A (CsA)
Number of subjects: 0
Study 11877070 — intervention group
Group type: COMPARATOR
Intervention: Androgen alone
Number of subjects: 0
Study 10463321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine infusion (bolus of 0.26 mg/kg followed by 0.65 mg/kg per hour) with oral haloperidol 5 mg
Number of subjects: 20
Study 10463321 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketamine infusion (bolus of 0.26 mg/kg followed by 0.65 mg/kg per hour) with matched placebo
Number of subjects: 20
Study 8667595 — intervention group
Group type: EXPERIMENTAL
Intervention: Antineoplaston A-10 oral formulation (14 patients)
Number of subjects: 42
Study 8667595 — intervention group
Group type: EXPERIMENTAL
Intervention: Antineoplaston A-10 injectable formulation (25 patients)
Number of subjects: 42
Study 8667595 — intervention group
Group type: EXPERIMENTAL
Intervention: Antineoplaston AS2-1 oral formulation (33 patients)
Number of subjects: 42
Study 8667595 — intervention group
Group type: EXPERIMENTAL
Intervention: Antineoplaston AS2-1 injectable formulation (10 patients)
Number of subjects: 42
Study 8667595 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with Antineoplastons
Number of subjects: 42
Study 2628135 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy with Roux-en-Y diversion
Number of subjects: 22
Study 2628135 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy with Billroth II reconstruction
Number of subjects: 22
Study 2628135 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative follow-up (6 months)
Number of subjects: 22
Study 841647 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination (intrademal injection)
Number of subjects: 8856
Study 841647 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial tuberculin reaction of 4 mm or greater
Number of subjects: 8856
Study 841647 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccinated group
Number of subjects: 8856
Study 841647 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 8856